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Abstract: BACKGROUND With increasing life expectancy in the western world, the aging population
will compose a significant portion of the demographic. Notably, cardiovascular disease is particularly
prevalent in the elderly population. The aim of the present study is to investigate the outcomes of oc-
togenarians referred for urgent coronary angiography in the setting of acute coronary syndromes (ACS).
METHODS Between June 2007 and June 2012, consecutive patients with ACS were referred for evalua-
tion and percutaneous intervention. Subsequently, the in-hospital death and major adverse cardiovascular
events (MACE) at 30 days were analyzed. Multivariate analysis was performed to identify the predic-
tors for death and MACE. RESULTS In patients ฀80 years (n = 296) ST-segment elevation myocardial
infarction (STEMI) occurred in 46.6 %, non-ST-segment elevation myocardial infarction (NSTEMI) in
45.9 %, and 7.4 % had unstable angina. On the other hand, in patients <80 years (n = 2,316) STEMI
was observed in 53.4 %, NSTEMI in 37.8 % and unstable angina in 9.0 %. The primary end-point of total
mortality was significantly higher in octogenarians (7.4 vs. 4.5 %, p = 0.026). Similarly, the secondary
end-point comprising overall MACE rate was significantly higher among the elderly (12.5 vs. 7.3 %,
p = 0.002). Within the group of octogenarians, no relation between age and outcomes was noted (for
death: OR 0.99, 95 % CI 0.84-1.16, p = 0.915; and for MACE: OR 1.10, 95 % CI 0.88-1.36, p = 0.412);
however, in patients <80 years, age was related to outcomes (for death: OR 1.05, 95 % CI, 1.02-1.08, p
= 0.003; and for MACE: OR 1.03, 95 % CI, 1.01-1.05, p = 0.011). In a multivariate analysis, systolic
blood pressure (OR 0.97 95 % CI 0.94-0.99, p = 0.0058), maximal value of creatine kinase (OR 1.00,
95 % CI 1.00-1.00, p = 0.033), and maximal value of NT-proBNP (OR 1.00, 95 % CI 1.00-1.00, p =
0.0225) were independent predictors for death, while systolic blood pressure (OR 0.98, 95 % CI 0.96-0.99,
p = 0.0384) and maximal value of C-reactive protein (OR 1.01, 95 % CI 1.00-1.01, p = 0.0265) were
associated with overall MACE. CONCLUSIONS Here we confirm that in-hospital death and MACE rate
remain significantly elevated in octogenarians in spite of implementation of modern therapies. However,
our real-world registry strongly suggests that early revascularization appears safe and effective in elderly
patients. Furthermore, we have identified that systolic blood pressure, creatine kinase, NT-proBNP, and
C-reactive protein are strong predictors for outcomes in octogenarians.
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Abstract
Background With increasing life expectancy in the wes-
tern world, the aging population will compose a significant
portion of the demographic. Notably, cardiovascular dis-
ease is particularly prevalent in the elderly population. The
aim of the present study is to investigate the outcomes of
octogenarians referred for urgent coronary angiography in
the setting of acute coronary syndromes (ACS).
Methods Between June 2007 and June 2012, consecutive
patients with ACS were referred for evaluation and per-
cutaneous intervention. Subsequently, the in-hospital death
and major adverse cardiovascular events (MACE) at 30
days were analyzed. Multivariate analysis was performed
to identify the predictors for death and MACE.
Results In patients C80 years (n = 296) ST-segment
elevation myocardial infarction (STEMI) occurred in
46.6 %, non-ST-segment elevation myocardial infarction
(NSTEMI) in 45.9 %, and 7.4 % had unstable angina. On
the other hand, in patients\80 years (n = 2,316) STEMI
was observed in 53.4 %, NSTEMI in 37.8 % and unstable
angina in 9.0 %. The primary end-point of total mortality
was significantly higher in octogenarians (7.4 vs. 4.5 %,
p = 0.026). Similarly, the secondary end-point comprising
overall MACE rate was significantly higher among the
elderly (12.5 vs. 7.3 %, p = 0.002). Within the group of
octogenarians, no relation between age and outcomes was
noted (for death: OR 0.99, 95 % CI 0.84–1.16, p = 0.915;
and for MACE: OR 1.10, 95 % CI 0.88–1.36, p = 0.412);
however, in patients \80 years, age was related to out-
comes (for death: OR 1.05, 95 % CI, 1.02–1.08,
p = 0.003; and for MACE: OR 1.03, 95 % CI, 1.01–1.05,
p = 0.011). In a multivariate analysis, systolic blood
pressure (OR 0.97 95 % CI 0.94–0.99, p = 0.0058),
maximal value of creatine kinase (OR 1.00, 95 % CI
1.00–1.00, p = 0.033), and maximal value of NT-proBNP
(OR 1.00, 95 % CI 1.00–1.00, p = 0.0225) were inde-
pendent predictors for death, while systolic blood pressure
(OR 0.98, 95 % CI 0.96–0.99, p = 0.0384) and maximal
value of C-reactive protein (OR 1.01, 95 % CI 1.00–1.01,
p = 0.0265) were associated with overall MACE.
Conclusions Here we confirm that in-hospital death and
MACE rate remain significantly elevated in octogenarians
in spite of implementation of modern therapies. However,
our real-world registry strongly suggests that early revas-
cularization appears safe and effective in elderly patients.
Furthermore, we have identified that systolic blood pres-
sure, creatine kinase, NT-proBNP, and C-reactive protein
are strong predictors for outcomes in octogenarians.
Keywords Acute coronary syndrome  Octogenarians 
Invasive treatment
W. Maier and C. Templin authors contributed equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s00392-014-0756-5) contains supplementary
material, which is available to authorized users.
M. Jaguszewski  J.-R. Ghadri  J. Diekmann 
R. D. Bataiosu  A. Siddique  L. Baumann 
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Introduction
Cardiovascular diseases remain a major public health
concern in the industrialized world, particularly due to an
increased prevalence of the elderly population [1]. The
World Health Organization (WHO) has estimated that by
2,050 the number of people older than 65 years of age will
represent 20 % of the total world’s population [2]. There-
fore, it is not surprising that the number of octogenarians
requiring urgent angiography due to acute coronary syn-
drome (ACS) has also increased in recent years [3]. Data
regarding optimal treatment of the elderly with ACS con-
tinue to remain scarce. The current ACS guidelines do not
distinguish between elderly and younger patients and rec-
ommend early revascularization for symptomatic relief and
avoidance of thrombolytics [4–7]. However, in many
centers primary percutaneous coronary intervention (pPCI)
is not regularly employed in octagenarians [3, 8]. Indeed,
elderly patients are underrepresented in clinical trials
investigating different treatment strategies that may explain
in part why elderly patients with ACS are less likely to
receive evidence-based treatment [9, 10].
Previously published observations from the Global
Registry of Acute Coronary Events (GRACE) highlighted
the need for evidence-based therapies for the elderly with
ACS [3]. Given the scarcity of data on outcome of elderly
patients with ACS undergoing urgent angiography and
pPCI, we investigated outcomes of octogenarians receiving
state-of-the-art treatment in a tertiary medical center.
Methods
Data extraction
From 2007 to 2012, consecutive patients referred for urgent
angiography due to ACS at the University Heart Center of
the University Hospital of Zurich were included in the
Zurich Acute Coronary Syndrome (Z-ACS) Registry.
Secondly, the population was divided into two groups
determined base on the age as follows: including patients
C80 years old (n = 296) and below 80 years (n = 2,316).
Myocardial infarction was defined based on the defini-
tion extracted from Thygesen et al. [11]. ST-segment ele-
vation myocardial infarction (STEMI) was defined as ST-
segment elevation or left bundle branch block on initial
ECG and elevation of cardiac markers. Non-ST-segment
elevation myocardial infarction (NSTEMI) was defined in
case of angina symptoms and/or ECG changes and elevated
cardiac markers. Unstable angina (UA) was diagnosed in
presence of angina symptoms and/or ECG changes and
normal values of cardiac markers. Stroke was assessed
independently by a neurologist and classified based on
focal neurologic deficits lasting longer than 24 h with a
clinical relevant lesion visualized on brain imaging. Car-
diovascular risk factors were defined as follows: hyper-
tension, diabetes mellitus, and/or dyslipidemia [12]. Family
history was considered significant, if a first-degree relative
younger than 55 year old (male) or 65 year old (female)
suffered premature CVD [12]. Obesity was defined as body
mass index C 30 kg/m2 [12].
Cardiogenic shock was defined as persistent systolic
blood pressure (SBP)\90 mmHg not responsive to fluid
resuscitation or requiring vasopressors agents with evi-
dence of pulmonary edema and systemic signs of hypo-
perfusion [13].
The electronic database (KISIM) provided information
regarding baseline characteristics, cardiovascular risk fac-
tors, patients’ cardiovascular medication on admission,
laboratory values, hemodynamic parameters, and the ther-
apeutic modality performed at our institution.
Due to the retrospective nature of this study, the need for
informed consent was waived by the institutional review
board (local ethics committee of the Canton of Zurich,
Switzerland).
Procedures
Coronary angiography was performed in all patients through
the femoral or radial access on an Allura 9, an Allura XPER
FD 10/10 (Philips Medical Systems) and Siemens Artis Zee
catheterization equipment in the Andreas Gruentzig Cathe-
terization Laboratories of the University Heart Center of the
University Hospital Zurich, Switzerland. The protocol con-
sisted of a biplane angiography of the left coronary artery
with two radiation exposures in four orientations and of the
right coronary artery with two exposures in two orientations.
Specific selection of guiding catheters, guidewires, type of
stents, thrombectomy were at the operator’s discretion.
Thrombectomy was performed using the Export catheter,
(Medtronic Inc., Tolochenaz, Switzerland). Intravenous
heparin was routinely administered with a minimal dose of
5,000 IE or 70–100 IU/kg to maintain an activated clotting
time (ACT) of greater than 250 s. Dual antiplatelet therapy
(DAPT) including a loading dose of 600 mg of clopidogrel,
60 mg of prasugrel or 180 mg of ticagrelor [14] and 500 mg
of acetylsalicylic acidwere provided to all patients before the
interventional treatment. After the percutaneous coronary
intervention (PCI) procedure, patients were expected to
continue DAPT for at least 12 months after discharge,
according to current available guidelines.
Outcome records
The primary end-point was in-hospital all-cause mortal-
ity. The secondary end-point included a composite of
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major adverse cardiovascular events (MACE) of death,
nonfatal myocardial infarction (MI), stroke and symp-
tom-driven subsequent percutaneous or surgical revascu-
larization. Furthermore, we dichotomized these outcomes
into an indicator variable defined by the type of ACS:
STEMI or NST-ACS. Patients’ outcomes for all-cause
in-hospital mortality and MACE were assessed at 30 day
of follow-up.
Statistical analysis
SPSS Statistics 20 (SPSS Inc., Chicago, IL, USA) was used
for the statistical analysis. The KSL test for normal distri-
bution was performed. Categorical variables were presented
as proportions, and continuous variables as mean values
(± standard error of the mean) or as median with inter-
quartile range if the variable was not normally distributed
(CK, CK-MB, Troponin T, and proBNP). Comparisons were
evaluated by Pearson’s Chi square for categorical variables
and Student’s t test for normally distributed variables.
Kruskal–Wallis test was used as nonparametric test. The
survival analysis was performed applying the Kaplan–Meier
method for both the primary and secondary end-points. The
curves were compared using the log-rank-sum test.
In an univariate nominal logistic regression model by
age group 80 years or older with all-cause death or MACE
as the outcome variables the following prespecified clinical
relevant covariates were included: age, heart rate, SBP,
aspirin and statin on admission, the use of gylcoprotein IIb/
IIIa inhibitor, maximal values of troponin, creatine kinase,
NT-proBNP, and C-reactive protein (CRP) were included.
The multivariate logistic regression included all covariates
mentioned above to demonstrate changes in significance. A
multivariate analysis was also performed to find high-risk
subsets of patients C80 years who underwent PCI.




Number of octogenarians referred for urgent diagnostic
angiography appeared to increase over time (2007–2009
vs. 2010–2012: 10.1 vs. 12.5 %, p = 0.58). The percentage
of females was significantly higher in octogenarian popu-
lation as compared to patients \80 year old (41.9 vs.
20.7 %, p\ 0.001). STEMI was more common in younger
patients (p = 0.03, Table 1). Conversely, NSTEMI was
more common in the octogenarians. There was no signifi-
cant difference in the rate of cardiogenic shock (Killip IV)
between the populations (p = 0.92, Table 1). A history of
prior MI, hypertension, diabetes mellitus (DM) was more
prevalent in those C80 years of age. However, cigarette
smoking, obesity, and known family history were more
common in younger patients. Prior to admission, the use of
aspirin and clopidogrel was more common in C80 year old
than in younger patients (p\ 0.001, Table 1).
Hemodynamics and treatment strategy
By definition, all patients underwent coronary angiography.
Primary PCI was performed at similar rates in both groups of






Male 172 (58.1 %) 1,837 (79.3 %) \0.001
Age 83.6 ± 0.2 61.3 ± 0.2 \0.001
BMI (kg/m2) 27.4 ± 1.9 27.4 ± 0.1 \0.001
STEMI 138 (46.6 %) 1,233 (53.2 %) 0.03
NST-ACS 158 (53.4 %) 1,083 (46.8 %) 0.03
NSTEMI 136 (45.9 %) 875 (37.8 %) 0.007
UA 22 (7.4 %) 208 (9.0 %) 0.38
Cardiogenic shock 28 (9.5 %) 215 (9.3 %) 0.92
Cardiovascular history
Previous MI 43 (14.5 %) 233 (10.1 %) 0.017
Stroke 6 (2.0 %) 24 (1.0 %) 0.13
Cardiovascular risk factors
HTN 223 (75.3 %) 1,232 (53.2 %) \0.001
DM 68 (23.0 %) 419 (18.1 %) 0.036
Hyperlipidemia 104 (35.1 %) 923 (39.9 %) 0.14
Current Smoker 91 (30.7 %) 1,375 (59.4 %) \0.001
Obesity 32 (10.8 %) 518 (22.4 %) \0.001
FH 52 (17.6 %) 626 (27.0 %) 0.001
Medication on admission
Aspirin 165 (55.7 %) 818 (35.3 %) \0.001
Clopidogrel 68 (23.0 %) 303 (13.1 %) \0.001
Prasugrel 1 (0.3 %) 31 (1.3 %) 0.15
Ticagrelor 1 (0.3 %) 0 0.005
Statin 108 (36.5 %) 704 (30.4 %) 0.023
Beta-Blocker 118 (39.9 %) 628 (27.1 %) \0.001
ACE inhibitor 71 (24.0 %) 384 (16.6 %) 0.001
Diuretics 102 (34.5 %) 394 (17.0 %) \0.001
ARBS 57 (19.3 %) 319 (13.8 %) 0.009
CCB 43 (14.5 %) 202 (8.7 %) 0.001
Warfarin 28 (9.5 %) 64 (2.8 %) \0.001
Data are presented as n (%) or mean (±SEM)
STEMI ST segment elevation myocardial infarction, NSTACS Non-
ST-segment acute coronary syndrome, NSTEMI Non-ST-segment
elevation myocardial infarction, UA unstable angina, HTN hyperten-
sion, DM diabetes mellitus, FH known family history, ACE angio-
tensin-converting enzyme, ARBS angiotensin-receptor blocking
agents, CCB calcium-channel blocker
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C80 years and\80 years (p = 0.98, Table 2). No differ-
ences in the pPCI rate were noted between groups after
assigning STEMI vs. NSTEMI groups (Supplemental
Fig. 1). The surgical revascularization rate was very low, but
also similar in both populations (p = 0.20, Table 2). In
5.4 % of the octogenarians and 3.9 % of population of
\80 years of age a conservative strategy was chosen
(p = 0.21, Table 2).
Left ventricular ejection fraction (LVEF) was signifi-
cantly lower in octogenarians as compared to group
\80 years of age (p\ 0.001, Table 2). SBPwas higherwith
advanced age (p\ 0.001), while diastolic blood pressure
(DBP) was significantly lower in the elderly as compared to
patients\80 years of age (p\ 0.001, Table 2). The ana-
tomical distribution of infarct-related lesions was similar in
both groups (Table 2). Single-vessel disease was less com-
mon in octogenarians as compared to younger patients
(p\ 0.001, Table 2) and multivessel disease was more
prevalent in the elderly population (p\ 0.001, Table 2).
There was no difference between the groups regarding
vasopressor administration (p = 0.86, Table 2) or in the
use of intra-aortic balloon pumps (IABP; p = 0.61,
Table 2). Glycoprotein IIb/IIIa antagonists (GP IIb/IIIa)
were administered more frequently among younger
patients than in octogenarians (p\ 0.001, Table 2). How-
ever, the use of GP IIb/IIIa increased among octogenarians
over time (2007/09 vs. 2010/12: 5.6 vs. 16.5 %,
p = 0.004).
Octogenarians were slightly less likely to receive aspirin
(p = 0.039, Table 1); however, evidence-based dual anti-
thrombotic treatment was similarly applied in both study
populations (p = 0.11, Table 1). Statins and ACE inhibi-
tors were less likely prescribed in octogenarians, while
diuretics, angiotensin-receptor blocking agents (ARBS),
and warfarin were less commonly used in those\80 years
of age (Table 1).
Laboratory values
Troponin T levels on admission and peak during hospi-
talization were similar in both groups (Table 3). In con-
trast, NT-proBNP levels on admission and peak levels
during the hospitalization were significantly higher in the
patients[80 years of age (Table 3).
30-day outcomes
The primary end-point of death was significantly higher in
octogenarians as compared to those \80 years of age
(p = 0.026, Table 4). However, no difference in the rate of
reinfarction was noted (p = 0.63, Table 4). The secondary
end-point comprising the overall MACE rate was also
significantly higher among older population (p = 0.002;
Fig. 1; Table 4). No differences were observed in the rates
of stroke (p = 0.18), urgent surgical revascularization
(p = 0.47), and in-stent thrombosis (p = 0.14, Table 4).







PCI 273 (92.2 %) 2,137 (92.3 %) 0.98
CABG 7 (2.4 %) 89 (3.8 %) 0.20
Conservative 16 (5.4 %) 90 (3.9 %) 0.21
Medication acutely
Vesopressors 20 (6.8 %) 163 (7.0 %) 0.86
GP-IIb/IIIa 35 (11.8 %) 567 (24.5 %) \0.001
GP-IIb/IIIa bolus 34 (11.5 %) 552 (23.8 %) \0.001
GP-IIb/IIIa infusion 13 (4.4 %) 240 (10.7 %) 0.001
Abciximab 11 (3.7 %) 297 (12.8 %) \0.001
Eptifibatide 24 (8.1 %) 270 (11.7 %) 0.069
Emergency procedures
Intubation 15 (5.1 %) 189 (8.2 %) 0.062
Resuscitation 36 (12.2 %) 369 (15.9 %) 0.09
Out-of-hospital 17 (5.7 %) 197 (8.5 %) 0.10
In-hospital 19 (6.4 %) 172 (7.4 %) 0.53
IABP 28 (9.5 %) 241 (10.4 %) 0.61
Vital signs on admission
HR (b.p.m.) 73.5 ± 1.0 74.4 ± 0.3 0.31
SBP (mmHg) 132.0 ± 1.7 125.6 ± 0.6 \0.001
DBP (mmHg) 65.5 ± 1.0 70.6 ± 0.3 \0.001
Hemodynamic
parameters
LVEDP (mmHg) 20.8 ± 0.6 19.6 ± 0.2 0.076
LVEF (%) 47.7 ± 1.1 53.1 ± 0.3 \0.001
Location of the lesion
LM 8 (2.7 %) 38 (1.6 %) 0.19
LAD 137 (46.3 %) 1,042 (45.0 %) 0.67
LCX 45 (15.2 %) 461 (19.9 %) 0.054
RCA 92 (31.1 %) 731 (31.6 %) 0.87
Graft 14 (4.7 %) 42 (1.8 %) 0.001
Coronary angiography
findings
Single vessel 86 (29.1 %) 983 (42.4 %) \0.001
Multi vessel 209 (70.6 %) 1,313 (56.7 %) \0.001
Dissection 0 5 (0.2 %) 0.42
Spasm 1 (0.1 %) 8 (0.3 %) 0.98
Data are presented as n (%) or mean (±SEM)
STEMI ST-segment elevation myocardial infarction, NSTEMI Non-
ST-segment elevation myocardial infarction, UA unstable angina,
IABP intra-aortic balloon pump, HR heart rate, SBP systolic blood
pressure, DP diastolic blood pressure, LVEDP left ventricular end-
diastolic pressure, EF ejection fraction, LM left main artery, LAD left
anterior descending artery, LCX left circumflex artery, RCA right
coronary artery
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Only a trend toward more urgent PCI rate was noted in
octogenarian patients (p = 0.054, Table 4). Additionally, a
trend toward a higher mortality in the elderly was docu-
mented in STEMI and NST-ACS subgroups (Supplemental
Fig. 2). However, elderly patients presenting with NSTE-
ACS had significantly higher MACE rates than younger
group (Supplemental Fig. 3).
Predictors of death and MACE
Interestingly, no relationship between age and outcomes
was noted in patients C80 years of age; however, among
patients\80 years old, age was associated with a higher
mortality (Supplemental Tables 1–2 and Supplemental
Fig. 4). The odds ratios for MACE by a categorized age
model showed a clear increasing risk of MACE with age:
\60 years: OR 0.74 (95 % CI 0.55, 0.99, p = 0.0462),
\70 years: OR 0.59 (95 % CI 0.44, 0.78, p = 0.0003),
\80 years: OR 0.55 (95 % CI 0.38, 0.81, p = 0.0034),
\85 years: OR 0.48 (95 % CI 0.26, 0.98, p = 0.0454).
In multivariate analysis, SBP was an independent pre-
dictor of death and MACE in all patients, while the peak
levels of CRP predicted MACE among patients C80 years
of age. Similarly, peak levels of creatine kinase and NT-
proBNP were independent predictors for death in patients
of C80 years of age. SBP on admission (p = 0.001) and
CRP on admission (p = 0.048) were found to be inde-
pendent risk factors of MACE in the octogenarian popu-
lation undergoing PCI. Patients with lower SBP and higher
CRP had significantly worse outcome as compared to those
with higher SBP and lower CRP.
The result of the multivariate analysis is presented in
Supplemental Tables 1 and 2.
Discussion
Our study illustrates several crucial findings. First, the
prevalence of octogenarians with ACS admitted to a ter-
tiary medical center with pPCI capacity has increased over
time. Second, octogenarians had higher 30-day mortality
and a higher MACE rate compared to younger patients in
spite of prompt acute revascularization and optimal medi-
cal therapy. This difference however, appears to be less
than the number reported in previously published series [3,
15, 16]. Third, octogenarians exhibited more comorbidi-
ties, extensive coronary artery disease, and lower LVEF
compared to younger patients. Finally, age itself was
documented as a risk factor for MACE or all-cause death.
No data exist to supporting the notion that octogenarians
should be treated differently than younger ACS patients
[7]. Indeed, current guidelines on myocardial revasculari-
zation suggest similar or even greater benefit of elderly
patients from early invasive treatment [7, 17]. However,
many studies and registries have documented that elderly
patients are less likely to receive evidence-based therapies
and are frequently admitted to facilities without a cathe-
terization laboratory and revascularization capabilities [3,
18]. In line with these findings, the GRACE and the Swiss
AMIS plus registry documented decreased rates of coro-
nary angiography and PCI in patients of advanced age [3,
8, 10]. One possible explanation for this observation is the






Cholesterol 4.3 (±0.1) 4.9 (±0.1) \0.001
HDL 1.2 (±0.1) 1.1 (±0.1) 0.001
LDL 2.6 (±0.1) 3.2 (±0.1) \0.001
TG 1.1 (±0.1) 1.4 (±0.1) \0.001
CRP on ad 20.5 (±2.5) 15.3 (±0.8) 0.005
CRP max 61.4 (±5.3) 57.9 (±2.0) 0.012
WBC on ad 9.9 (±0.2) 11.1 (±0.1) \0.001
WBC max 11.4 (±0.3) 12.7 (±0.1) \0.001
CK on ad 181.5 (46.6) 217.0 (351.5) 0.006
CK max 476.0 (186.1) 827.5 (1,243.3) \0.0001
CK-MB on ad 35.0 (68) 33.0 (52.5) 0.7981
CK-MB max 62.0 (197) 91.0 (167.5) 0.005
Troponin T on ad 0.25 (0.84) 0.19 (0.869) 0.0828
Troponin T max 1.46 (4.89) 1.92 (5.01) 0.1986
proBNP on ad 1803.0 (1,291.5) 371.0 (4,226) \0.0001
proBNP max 3,716.5 (2,322) 1,071.0 (7,681.5) \0.0001
Data are presented as mean (±SEM), CK, CK-MB, Troponin and
proBNP are presented as median (IQR)
STEMI ST-segment elevation myocardial infarction, NSTEMI Non-
ST-segment elevation myocardial infarction, UA unstable angina,
HDL high-density lipoprotein, LDL low-density lipoprotein, TG tri-
glycerides, CRP c-reactive protein, WBC white blood count, CK
creatine kinase, CK-MB creatine kinase-MB fraction, BNP brain







Death 22 (7.4 %) 104 (4.5 %) 0.026
MI 5 (1.7 %) 31 (1.3 %) 0.63
Stroke 3 (1.0 %) 9 (0.4 %) 0.18
Urgent PCI 14 (4.7 %) 63 (2.7 %) 0.054
CABG 0 4 (0.2 %) 0.47
MACE 37 (12.5 %) 169 (7.3 %) 0.002
Data are presented as n (%)
CABG coronary artery bypass graft, MACE major adverse cardio-
vascular events,MImyocardial infarction, PCI percutaneous coronary
intervention
Clin Res Cardiol (2015) 104:51–58 55
123
delay in implementing the proper evidence-based treatment
for elderly patients due to the atypical initial presentation
and concomitant comorbidities [19, 20]. Indeed, the elderly
are still underrepresented in randomized controlled trials
(RCT) which does not correspond to the clinical practice
[3]. Existing data indicate that recruitment of these patients
to RCTs could improve their compliance [4]. Also,
aggressive interventional approach in the acute course of
STEMI or moderate and high-risk NSTEMI could poten-
tially improve outcomes in the oldest subset of patients. A
registry, particularly one including data from elderly pop-
ulation is desperately needed to assess outcome and safety
of modern management in this growing population. This
was our motivation to investigate treatment strategies in
octogenarians with ACS referred for urgent intervention.
Of note, a trend in increasing number of referrals of
octogenarians was observed most recent 3-year observation
period compared to 2007 to 2009. In contrast to other
previously published studies, we did not observe any sig-
nificant differences in DAPT therapy or interventional
treatment between octogenarians and patients below
80 years of age [3, 21, 22]. Indeed, the rate of interven-
tional approaches including pPCI and bypass surgery to
treat ACS was very high regardless of age. Interestingly,
contrary to current practice [3, 21, 23], invasive treatment
was similarly applied in patients with NSTE-ACS in both
groups of age. It has been demonstrated that routine early
invasive strategy can significantly improve cardiovascular
outcomes in elderly patients with NSTE-ACS [24].
In our series, the mortality rate was very low in both
groups averaging 7.4 % in C80 and 4.5 % in those
\80 years of age. The higher mortality in the elderly in our
series is likely related to a higher prevalence of female
gender, more comorbidities, more extensive coronary
artery disease and a lower LVEF at presentation [22, 25].
Overall, our results are more favorable compared to other
large studies, where evidence-based treatment and early
revascularization were less frequently implemented in the
elderly population [15, 16, 26]. In the Euroheart acute
coronary syndrome survey the mortality rate in patients
aged 75–84 was 8.0 % and those C85 years of age 16.8 %
[15]. In the Maximal Individual Therapy in Acute Myo-
cardial Infarction (MITRA) registry, the in-hospital mor-
tality for patients aged[75 years was even higher (21.8 %)
and patients aged [85 years showed a mortality rate of
29.4 % when the reperfusion therapy was initiated [16].
The mortality rate in the octogenarian population at our
institution is consistent with the German ALKK registry,
where interventional treatment of ACS and success rate
were relatively high compared to prior studies and regis-
tries [27]. This strongly suggests that early revasculariza-
tion is not only effective but even more beneficial in the
elderly population. Stroke was not a safety issue with pPCI
in this population in spite of the use of DAPT and a
comparable use of glycoprotein IIB/IIIA inhibitors. The
relatively low mortality rate is also due to a well-organized
healthcare system in Switzerland [28]. Moreover, the use
of drug-eluting stents (DES) in more than 80 % patients
between 2007 and 2010 may also contributed to the better
overall outcome [29].
As anticipated, the primary and secondary end-points
were significantly more prevalent in elderly patients.
However, in a multivariate analysis, age was an indepen-
dent predictor for outcomes in younger patients only. This
suggests that even very elderly may benefit from early
reperfusion. In spite of considerable comorbidities, the
elderly have a considerable life expectancy when appro-
priately treated. Indeed, after stratifying into STEMI and
NSTE-ACS, only a trend toward higher mortality rate in
octogenarians was observed. However, the groups were
probably too small to reach any statistically meaningful
conclusion.
As reported previously, maximal values of CRP were
associated with poor outcomes in both subpopulations [30].
Only smoking was inversely related to age, possibly
because smokers have a shorter life expectancy and,
therefore, do not reach older age in similar numbers [31].
The higher inflammatory nature in elderly patients may be
worth investigating as a potential issue for further studies.
Limitations
Our cohort included patients from a single tertiary care
center, where all patients were referred for urgent angi-
ography. Data regarding patients treated in conservative
Fig. 1 Kaplan–Meier survival curves for 30-day MACE for C80 and
\80 year old groups demonstrating an unfavorable outcome for
patients above 80 (p = 0.002)
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manner in the referring hospitals are, therefore, lacking.
Second, due to the lack of data on comorbidities, we are
unable to assess their impact in overall MACE in elderly
patients. Furthermore, the study is retrospective in nat-
ure; however, the all-comer design minimized selection
bias and provided real-life results. Also, most data were
collected prospectively in the hospital information
system.
Conclusions
Herein we confirm that in-hospital death and MACE rate
remain significantly elevated in octogenarians. In the
absence of data from RCTs, real-world registry data such
as that from the present Z-ACS registry, strongly suggest
that reperfusion using pPCI appears safe and effective
despite the age. Furthermore, SBP, creatine kinase, NT-
proBNP, and CRP are strong predictors for outcomes in
octogenarians.
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